ELECTROPHYSIOLOGY

Prevalence of Atrial Fibrillation in Patients with High CHADS$_2$- and CHA$_2$DS$_2$VASc-Scores: Anticoagulate or Monitor High-Risk Patients?

TINA S. TISCHER, M.D.,* RALPH SCHNEIDER, M.D.,* JÖRG LAUSCHKE, M.D.,* CATHARINA NESSELMANN, M.D.,* ANKE KLEMM,† DOREEN DIEDRICH,‡ GÜNTHER KUNDT, Ph.D.,‡ and DIETMAR BÄNSCH, M.D.*

From the *Heart Center Rostock, University Hospital, Rostock, Germany; †Department of Controlling, University Hospital, Rostock, Germany; and ‡Institute for Biostatistics and Informatics in Medicine and Ageing Research, University Hospital, Rostock, Germany

**Background:** In patients with known atrial fibrillation (AF) different scores are utilized to estimate the risk of thromboembolic events and guide oral anticoagulation. Diagnosis of AF strongly depends on the duration of electrocardiogram monitoring. The aim of this study was to use established scores to predict the prevalence of AF.

**Methods:** The CHADS$_2$- (Congestive Heart failure, hypertension, Age > 75 years, Diabetes, Stroke [doubled]) and CHA$_2$DS$_2$VASc-score (Congestive Heart failure, hypertension, Age ≥ 75 years [doubled], Diabetes, Stroke [doubled], Vascular disease, Age 65–74 years, Sex category [female sex]) was calculated in 150,408 consecutive patients, referred to the University Hospital of Rostock between 2007 and 2012. All factors constituting these scores and a history of AF were prospectively documented with the ICD-10 admission codes.

**Results:** Mean age of our study population was 67.6 ± 13.6 years with a mean CHADS$_2$-score of 1.65 ± 0.92 and CHA$_2$DS$_2$VASc-score of 3.04 ± 1.42. AF was prevalent in 15.9% of the participants. The prevalence of AF increased significantly with every CHADS$_2$- and CHA$_2$DS$_2$VASc-score point up to 54.2% in CHADS$_2$-score of 6 and 71.4% in CHA$_2$DS$_2$VASc-score of 9 (P < 0.001).

**Conclusion:** The prevalence of AF increases with increasing CHADS$_2$- and CHA$_2$DS$_2$VASc-score. In intermediate scores intensified monitoring may be recommended. In high scores, thromboembolic complications occurred irrespective of the presence of AF and anticoagulant therapy may be initiated irrespective of documented AF. (PACE 2014; 37:1651–1657)

atrial fibrillation, prevalence, risk factors, stroke prevention

---

**Introduction**

Atrial fibrillation (AF) is a frequent arrhythmia with an estimated prevalence of 1.5–2% in developed countries. The occurrence is suspected to rise due to an ageing population and the progressive nature of the arrhythmia. AF is associated with increased morbidity, mortality, and risk of thromboembolism, which can be significantly reduced with oral anticoagulation. The CHADS$_2$- (Congestive Heart failure, hypertension, Age > 75 years, Diabetes, Stroke [doubled]) and CHA$_2$DS$_2$VASc- (Congestive Heart failure, hypertension, Age ≥ 75 years [doubled], Diabetes, Stroke [doubled], Vascular disease, Age 65–74 years, Sex category [female sex]) score have been established to guide antithrombotic therapy in individuals with known AF. However, AF is often not diagnosed until patients present with thromboembolic complications. In up to 25% of patients, AF is suspected to be the cause of a cryptogenic
Therefore, early identification of individuals with AF seems to be warranted in order to prevent associated complications.\textsuperscript{1,8} Many efforts have been undertaken to create models for the identification of patients at risk of AF before complications become apparent. So far, risk stratification has been limited to small cohorts or restricted age groups. Finally, risk stratification was not easily adopted in daily practice.\textsuperscript{3,15} The CHADS\textsuperscript{2}- and CHA\textsubscript{2}DS\textsuperscript{2}-VASc-score are well-established tools to estimate the risk of thromboembolic events in individuals with known AF.\textsuperscript{1,8,12,13} Some features of these scores are not only used to predict the risk of thromboembolic complications, but also to predict the occurrence of AF.\textsuperscript{3,8,15} In this study, we hypothesized that the CHADS\textsuperscript{2}- and CHA\textsubscript{2}DS\textsuperscript{2}-VASc-score may predict the prevalence of AF and may be used to guide cardiac monitoring.

**Methods**

A total of 150,408 patients who were referred to different medical departments in the University Hospital of Rostock between January 1, 2007 and December 31, 2012 were included in this study. The CHADS\textsuperscript{2}- and CHA\textsubscript{2}DS\textsuperscript{2}-VASc-scores were prospectively and electronically documented using the International Statistical Classification of Diseases, 10th Revision (ICD-10) codes: Hypertension (ICD-10 codes I10–I15), previous transient ischemic attack (TIA), stroke or arterial thromboembolism (ICD-10 codes G45.9, I63.0–I63.9, and I74–I74.9), congestive heart failure (ICD-10 codes I50.00–I50.01, I50.9, I50.11–I50.14, and I50.19 ), and diabetes (ICD-10 codes E10.0–E14.91). In addition, vascular diseases such as myocardial infarction (ICD-10 codes I21.0–I21.9, I22.0–I22.9, and I25.20–I25.29), coronary artery disease (ICD-10 codes I25.0–I25.19), peripheral arterial occlusive disease (ICD-10 codes I70.2–I70.25), or atherosclerosis of the aorta (ICD-10 code I70.0) were documented. Age at the time of admission and gender were also recorded in all patients. Based on this data, the CHADS\textsuperscript{2}- and CHA\textsubscript{2}DS\textsuperscript{2}-VASc-score was calculated for each patient. Finally, patients were identified with an admission code of AF (ICD-10 codes I48.0–I48.2, and I48.9) based on anamnestic data, electrocardiogram (ECG)-recording, Holter monitoring, and data from cardiac devices. Precisely, in patients with anamnestic AF there had to be at least one ECG with documented AF before hospitalization, based on a physician recall. In patients with first detected AF during the hospital stay, we used ECG recording, Holter monitoring, and also data from loop recorders and cardiac devices for the diagnosis of AF. An episode of AF was defined as an event lasting greater than 30 seconds in duration. Patients with paroxysmal as well as persistent AF were included in our study.

**Statistical Analysis**

All data were stored and analyzed using the SPSS statistical package 21.0 (IBM Corp., Armonk, NY, USA). Descriptive statistics were computed for continuous and categorical variables. The statistics computed included mean and standard deviation (SD) of continuous variables and are presented as mean ± SD, frequencies, and relative frequencies of categorical factors.

Comparisons between groups for categorical variables were done using the $\chi^2$ or Fisher’s exact test and for continuous variables using a t-test for independent samples. The logistic regression model was used to evaluate the influence of several factors constituting the scores on risk for AF. Evaluation was done by computation of odds ratios (OR), 95% confidence intervals (95% CI), and examination the significance of the Wald statistic. All P values resulted from two-sided statistical tests and values of P < 0.05 were considered to be statistically significant.

**Results**

A total of 150,408 patients were included in the study; mean age was 67.6 ± 13.6 years (Table I). A total of 46,602 patients (31%) were between 65 years and 74 years and 51,720 older than 74 years of age (34.4%, Table I). The majority (56.9%) were male. AF was known in 23,905 patients (15.9%) with a mean age of 72.8 ± 10.5 years (Table I). Of 150,408 patients, 80.2% suffered from hypertension. Diabetes mellitus was present in 35.3% and vascular diseases in 30.4% of patients. Congestive heart failure was documented in 10.2%, a history of TIA or stroke in 4.0% of patients.

**CHADS\textsuperscript{2}-Score**

The mean CHADS\textsuperscript{2}-score was 1.65 ± 0.92. The prevalence of AF was 10.1%, 15.5%, 25.8%, 37.4%, 45.9%, and 54.2% in patients with a CHADS\textsuperscript{2}-score between 1 and 6, respectively (Table II, Fig. 1). This prevalence of AF increased continuously and significantly by 5.4–11.5% with every score point (P < 0.001).

The rising prevalence of AF with an increasing CHADS\textsuperscript{2}-score was present in the whole cohort irrespective of the medical department patients were admitted to and the underlying disease that caused the hospitalization (Table II). The prevalence was highest in patients who were admitted to cardiology and cardiac surgery because AF was the reason for admission in many patients. Still, the prevalence increased with an increasing score. Overall, the prevalence of AF was significantly increased in patients older than 74 years of age (OR = 2.09, 95% CI: 2.04–2.15), with congestive heart...
Table I.
Baseline Characteristics

| Variable                      | n   | %  | Without AF | n   | %  | With AF | n   | %  | P Value |
|-------------------------------|-----|----|------------|-----|----|---------|-----|----|---------|
| Patients                      | 150,408 | 100 | 126,503 | 84.1 | 23,905 | 15.9 |
| Age (mean ± SD) years         | 67.6 ± 13.6 | 66.6 ± 13.9 | 72.8 ± 10.5 | 67.8 ± 13.6 | 30.8 | 7608 | 15.9 | <0.001 |
| Age <65 years                 | 52,086 | 34.6 | 47,577 | 37.6 | 4,544 | 19.0 |
| Age 65–74 years               | 46,602 | 31.0 | 38,994 | 30.8 | 7,608 | 31.8 |
| Age >74 years                 | 51,720 | 34.4 | 39,932 | 31.6 | 11,753 | 49.2 |
| Age >75 years                 | 46,286 | 30.8 | 35,567 | 28.1 | 10,665 | 44.6 |
| Female                        | 64,835 | 43.1 | 47,577 | 37.6 | 10,087 | 42.2 |
| Congestive heart failure      | 15,326 | 10.2 | 9,932 | 7.9 | 5,394 | 22.6 |
| Hypertension                  | 120,631 | 80.2 | 102,830 | 81.3 | 17,801 | 74.5 |
| Diabetes mellitus             | 53,115 | 35.3 | 44,236 | 35.0 | 8,879 | 37.1 |
| History of stroke             | 5,984 | 4.0 | 4,302 | 3.4 | 1,682 | 7.0 |
| Vascular disease              | 45,755 | 30.4 | 36,603 | 28.9 | 9,152 | 38.3 |

AF = atrial fibrillation; SD = standard deviation.

Table II.
Prevalence of Atrial Fibrillation with Increasing CHADS₂-Score and Main Reason for Hospitalization

| CHADS₂-Score | All | Cardiology/ Cardiac Surgery | Dermatology | Neurology | Surgery | Otorhinolaryngology | Ophthalmology | Prevalence of AF (%) |
|--------------|-----|-------------------------------|-------------|-----------|---------|---------------------|---------------|---------------------|
| 1            | 10.1 | 21.2                          | 10.7        | 6.0       | 6.2     | 3.7                | 3.0           |                     |
| 2            | 15.5 | 26.2                          | 17.1        | 15.0      | 10.8    | 7.9                | 4.3           |                     |
| 3            | 25.8 | 36.7                          | 29.4        | 22.7      | 19.0    | 13.8               | 5.8           |                     |
| 4            | 37.4 | 45.2                          | 40.6        | 32.2      | 36.7    | 22.9               | 75.0          |                     |
| 5            | 45.9 | 60.0                          | 35.7        | 44.9      | 68.0    | 28.6               | 25.0          |                     |
| 6            | 54.2 | 38.5                          | 20.0        | 57.1      | 88.9    | 100.0              | 0             |                     |

Mean ± SD‡ 1.65 ± 0.92

CHADS₂-Score = Congestive Heart failure, hypertension, Age >75 years, Diabetes, Stroke (doubled); SD = standard deviation.

The prevalence of stroke increased from 0% to 93.8% between a CHADS₂-score of 1 and 6 (Table IV). Up to a score of 3, the prevalence of stroke was higher in patients with known AF. Beyond a score of 3, patients showed a high prevalence of stroke irrespective of AF (Table IV). The prevalence of stroke increased from 0% to 93.8% between a CHADS₂-score of 1 and 6 (Table IV). Up to a score of 3, the prevalence of stroke was higher in patients with known AF. Beyond a score of 3, patients showed a high prevalence of stroke irrespective of AF (Table IV).

CHADS₂ DS₂ VASc-Score

Table III. The mean CHADS₂ DS₂ VASc-score was 3.04 ± 1.42 in the whole cohort. The prevalence of AF increased progressively and significantly from 9.9% in patients with a CHADS₂ DS₂ VASc-score of 1–71.4% in patients with a CHADS₂ DS₂ VASc-score of 9 (P < 0.001, Table V, Fig. 1). The increasing prevalence of AF in patients with increasing CHADS₂ DS₂ VASc-scores was apparent in all medical departments and irrespective of the underlying disease that lead to the hospitalization (Table V, Fig. 2).

Comparable to the CHADS₂-score the prevalence of AF was also higher in cardiology and cardiac surgery patients and increased with an increasing score. The logistic regression analyses of factors constituting the CHADS₂ DS₂ VASc-score revealed the same results for age, congestive heart failure, diabetes mellitus, history of stroke, and hypertension as the CHADS₂-score (Table III). In addition, female patients had a slightly decreased prevalence of AF compared with males (OR = 0.96, 95% CI: 0.93–0.98). Patients with vascular disease had an increased relative risk of AF (OR = 1.52, 95% CI: 1.48–1.57) (Table III).
The prevalence of stroke rose from zero to a maximum of 96.4% between CHA\textsubscript{2}DS\textsubscript{2}VASc-score 1 and 9 (Table VI). Up to a score of 6, the prevalence of stroke was higher in patients with AF. Beyond a score of 6, the prevalence of stroke was high irrespective of AF.

**Discussion**

**Prevalence of AF**

The prevalence of AF was 15.9% in our study population (mean age of 67.6 ± 13.6 years). In the general population aged over 65 years, the prevalence of AF is estimated to be between 6% and 8%.\textsuperscript{5,16,17} One reason for the higher prevalence in our study may be that many patients have been presented to our hospital for AF as reflected in the high prevalence of AF in patients who were admitted to “the cardiology-” or cardiac surgery department. Besides, patients revealed considerable comorbidities as depicted by a mean CHA\textsubscript{2}DS\textsubscript{2}VASc-score of 1.65 ± 0.92 and the mean CHA\textsubscript{2}DS\textsubscript{2}VASc-score of 3.04 ± 1.42. However, the increasing prevalence of AF with higher scores was apparent in all departments and independent of the reason for hospitalization. In addition, a
Table V.
Prevalence of Atrial Fibrillation with Increasing CHA₂DS₂-VASc-Score and Main Reason for Hospitalization

| CHA₂DS₂-VASc-Score | All | Cardiology/Cardiac Surgery | Dermatology | Neurology | Surgery | Oto-rhino-laryngology | Ophthalmology |
|---------------------|-----|---------------------------|-------------|-----------|---------|------------------------|--------------|
| 1                   | 9.9 | 31.9                      | 9.1         | 4.7       | 5.0     | 2.7                    | 3.1          |
| 2                   | 9.9 | 20.6                      | 10.5        | 6.4       | 6.7     | 4.5                    | 3.4          |
| 3                   | 14.2| 23.0                      | 16.5        | 12.0      | 10.1    | 8.1                    | 3.9          |
| 4                   | 17.4| 25.3                      | 20.5        | 17.4      | 11.9    | 9.3                    | 4.7          |
| 5                   | 25.8| 30.6                      | 29.5        | 26.0      | 19.0    | 11.3                   | 6.9          |
| 6                   | 35.5| 35.8                      | 35.6        | 37.3      | 30.8    | 20.8                   | 20.0         |
| 7                   | 47.6| 47.9                      | 46.7        | 48.0      | 46.9    | 40.0                   | 50.0         |
| 8                   | 50.2| 41.2                      | 23.5        | 50.3      | 80.0    | 100                    | 100          |
| 9                   | 71.4| 50.0                      | 100         | 77.8      | 100     | 0                      | 0            |

Mean ± SD 3.04 ± 142

Abbreviations as in previous tables.

The prevalence of AF with up to 30–34% has been described in patients with intensified monitoring with implanted devices during a follow up of 1.1–2.5 years. In line with our data Engdahl et al. reported a prevalence of 14% in a population of 75 years and 76 years of age using a special screening program.

The Prevalence of AF and Thromboembolic Complications

In patients with known AF risk factors for stroke have been investigated in detail and “resulted in the widely accepted” CHADS₂- and CHA₂DS₂-VASc-score to identify patients who may benefit from oral anticoagulation. But little is known about the occurrence of AF in patients with stroke risk factors.

We could demonstrate that the prevalence of AF rises significantly with every CHADS₂- and CHA₂DS₂-VASc-score point, independent of the attending medical department and the underlying disease that lead to hospitalization. Patients with a CHADS₂-score of 5 and 6 had AF in 45.9% and 54.2%, respectively. Patients with a CHA₂DS₂-VASc-score between 6 and 9 had AF in 35.3% to 71.4%. In contrast to our study, Ziegler et al. detected AF in 30% of patients during a mean follow-up of 1.1 year with implantable loop recorders. The occurrence of AF was not related to underlying CHADS₂-score and the diagnosis was based on any episode of AF irrespective of symptoms. However, AF lasting longer than 6 hours/day was associated with a higher CHADS₂-score. This may indicate that the scores predict persistent and longer lasting episode of AF rather than short episodes of paroxysmal AF. In addition, Zuo et al. demonstrated that in patients without documented AF but arrhythmic symptoms, a high CHADS₂- and CHA₂DS₂-VASc-score was associated with a high risk of a new onset of AF.

In patients with CHADS₂-score of more than 4 and a CHA₂DS₂-VASc-score of more than 7 the prevalence of stroke was high and independent of AF.

In contrast, the prevalence of thromboembolic complications was two to five times higher with CHADS₂-score below 4 and CHA₂DS₂-VASc-score below 7, if AF was present.

We, therefore, conclude that using the CHADS₂- and CHA₂DS₂-VASc-score it may be possible to detect patients with a high risk of AF and thromboembolic complications if AF is present. With very high scores the risk of thromboembolic complications may no longer be dependent on AF. While intensified monitoring may be warranted in the former patients, anticoagulation may be warranted in the latter. This hypothesis should be tested in a prospective trial, which is underway in collaboration with Biotronik (Cleopatra Trial; Biotronik GmbH, Berlin, Germany). In this randomized trial, patients post-myocardial infarction with a CHADS₂-score of more than 2 undergo intensified monitoring with an implantable loop recorder.

Limitations

The study was carried out in a single community and there may be a selection bias, because all patients were referred to our hospital for various clinical reasons. However, the relationship
between the prevalence of AF and the CHADS\(_2\)- or CHA\(_2\)DS\(_2\)VASc-score was present in all departments irrespective of the reason for referral. In addition, these data were primarily collected to generate reimbursement from health insurances and not primarily for medical reasons. Clinical details such as the severity of AF were not documented. Furthermore, information concerning medication was not available. Nevertheless, in Germany under- and overcoding of diseases is under penalty, so documented data are expected to be very reliable.

Apart from that, in our study population the prevalence of AF was lower among hypertensive patients, although hypertension is considered to be a risk factor for the development of AF. We realized that the population of the eastern part of Germany has many chronic illnesses. The very fact that hypertension was prevalent in 80\% of the study patients shows that concerning this disease the study patients are not comparable to general population.

**Conclusion**

The prevalence of AF increased considerably with increasing CHADS\(_2\)- and CHA\(_2\)DS\(_2\)VASc-scores. The prevalence of thromboembolic complications was dependent on the presence of AF up to a CHADS\(_2\)-score of 3 and CHA\(_2\)DS\(_2\)VASc-score of 6. This should warrant intensified monitoring in these patients. The prevalence of thromboembolic complications was high and independent of the presence of AF in patients with a CHADS\(_2\)-score of 4 or more and CHA\(_2\)DS\(_2\)VASc-score of 7 or more. This may indicate that the need for anticoagulation may be independent of the documentation of AF. Both hypotheses should be prospectively verified.
References

1. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: An update of the 2010 ESC guidelines for the management of atrial fibrillation–developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14:1385–1413.

2. Lip GY, Tse HF, Lane DA. Atrial fibrillation. Lancet 2012; 379:648–661.

3. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D’Agostino RB Sr., Newton-Cheh C, et al. Development of a risk score for atrial fibrillation [Framingham Heart Study]: A community-based cohort study. Lancet 2009; 373:739–745.

4. de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen JM, van den Heijink AN, 3rd, Page RL, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 2016; 55:725–731.

5. Rho RW, Page RL. Asymptomatic atrial fibrillation. Prog Cardiovasc Dis 2005; 48:79–87.

6. Miyasaka Y, Barnes ME, Gersh BJ, Bailey KR, Abhayaratna WP, Seward JB, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114:119–125.

7. Kirchhof P, Breithardt G, Aliot E, Khatib SA, Apostolakis S, Auricchio A, Bailleul C, et al. Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European heart rhythm association consensus conference. Europace 2013; 15:1540–1556.

8. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, et al. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369–2429.

9. Benjamin EJ, PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98:946–952.

10. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA, 3rd, Page RL, et al. ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123:104–123.

11. Fuster V, Ryden LE, Cannon DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257–e354.

12. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285:2864–2870.

13. Lip GY, R. Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro heart survey on atrial fibrillation. Chest 2010; 137:263–272.

14. Liao J, Z, Scallan C, Morillo C, O’Donnell M. Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: A systematic review. Stroke 2007; 38:2935–2940.

15. Alonso A, Krijthe BP, Aspelund T, Stolp KA, Pencina MJ, Moser CJ, Sinner MF, et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: The CHARGE-AF consortium. J Am Heart Assoc 2013; 2:e000102.

16. Mullenix PS, Martin MJ, Steele SR, Lavenson GS Jr., Starnes BW, Hadro NC, Peterson RP, et al. Rapid high-volume population screening for three major risk factors of future stroke: Phase I results. Vase Endovasc Surg 2006; 40:177–187.

17. Co AS, Hylek EM, Phillips KA, Chang Y, Hanfua LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AtrialFibrillation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285:2370–2375.

18. Ziegler PD, Glotzer TV, Daoud EG, Singer DE, Ezekowitz MD, Hoyt RH, Koehler JL, et al. Detection of previously undiagnosed atrial fibrillation in patients with stroke risk factors and usefulness of continuous monitoring in primary stroke prevention. Am J Cardiol 2012; 110:1309–1314.

19. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366:120–129.

20. Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibrillation in a 75-year-old population: Implications for stroke prevention. Circulation 2013; 127:930–937.

21. Friberg E, Engdahl J, Frykman V, Svensberg E, Levin LA, Rosenqvist M. Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP). Europace 2013; 15:135–140.

22. Samol A, Masin M, Gellner R, Otte B, Pavenstadt HJ, Ringelstein EB, Reinecke H, et al. Prevalence of unknown atrial fibrillation in patients with risk factors. Europace 2013; 15:657–662.

23. Zuo ML, Liu S, Chan KH, Lau KK, Chong BH, Lam FP, Chan YH, et al. The CHADS2 and CHA2DS2-VASc scores predict new occurrence of atrial fibrillation and ischemic stroke. J Interv Card Electrophysiol 2013; 37:47–54.